Article
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
Leukemia & lymphoma - 1 Oct 2011
Miglino Maurizio, Colombo Nicoletta, Pica Gianmatteo, Grasso Raffaella, Clavio Marino, Bergamaschi Micaela, Ballerini Filippo, Ghiso Anna, Ghiggi Chiara, Mitscheunig Laura, Beltrami Germana, Cagnetta Antonia, Vignolo Luana, Lucchetti Maria Vita, Aquino Sara, Pierri Ivana, Sessarego Mario, Carella Angelo Michele, Gobbi Marco
Abstract excerpt
We reviewed the frequency and prognostic significance of FLT3 (fms-like tyrosine kinase receptor-3) and NPM (nucleophosmin) gene mutations and WT1 (Wilms' tumor) and BAALC (brain and acute leukemia, cytoplasmic) gene expression in 100 consecutive patients with intermediate and poor cytogenetic risk de novo acute myeloid leukemia (AML) receiving conventional anthracycline-AraC based therapy. We observed a strict...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
